Allergan Accelerates Transformation to Branded Growth Pharma Leader by Divesting Global Generics Business to Teva for $40.5 Billion

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. QQQ
8. UNFI
9. SPY
10. ASO

Go back to Allergan Accelerates Transformation to Branded Growth Pharma Leader by Divesting Global Generics Business to Teva for $40.5 Billion

Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale

July 28, 2015 9:13 AM EDT

Canaccord Genuity reiterated a Buy rating on Allergen (NYSE: AGN), and raised the price target to $396.00 (from $352.00), following the announced sale of its generics unit to Teva (NYSE: TEVA). Teva will acquire the unit for $40.5B.... More

Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement

July 28, 2015 8:19 AM EDT

Allergan (NYSE: AGN)
Leerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $388.00 (from $354.00), following this morning's announcement that TEVA will be acquiring AGNs Gx biz for $40.5B. Analyst Jason Gerberry views TEVA (OP) as the most suitable owner for the AGN's Gx assets.

Gerberry... More

Perrigo (PRGO) Gains After Teva (TEVA) Withdraws Proposal to Acquire Mylan (MYL)

July 27, 2015 7:25 AM EDT

Perrigo (NYSE: PRGO) gained after Teva Pharma (NYSE: TEVA) withdrew its proposal to acquire Mylan (NASDAQ: MYL). Tevas decision follows an announcement that Teva has entered into a definitive agreement with Allergan (NYSE:... More